Year: 2023

CICERO, Ill., Nov. 13, 2023 (GLOBE NEWSWIRE) — Broadwind, Inc. (Nasdaq: BWEN, “Broadwind” or the “Company”), a diversified precision manufacturer of specialized components and solutions serving global markets, today announced results for the third quarter 2023. THIRD QUARTER 2023 RESULTS(As compared to the third quarter 2022)Revenue of $57.2 million, +$12.3 million y/y GAAP Net Income of $4.4 million, or $0.20 per diluted share, +$6.2 million y/y Non-GAAP Adjusted EBITDA of $7.6 million, +$5.7 million y/y Ratio of net debt to trailing twelve-month Non-GAAP Adjusted EBITDA of 1.7x as of September 30, 2023 Total backlog of $220.8 million, +$88.6 million y/y, as of September 30, 2023 Reiterating full-year 2023 revenue and Adjusted EBITDA guidanceFor the three months ended September 30, 2023, Broadwind reported total revenue of...

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023Announced global collaboration and license agreement with Halozyme for development of a subcutaneous formulation of ACU193Initiation of a Phase 1 study to support a subcutaneous dosing option of ACU193 expected in mid-2024Announced a credit facility of up to $50 million from K2 HealthVentures, to provide capital to support subcutaneous clinical work and general corporate purposesCSF biomarker data observed in the Phase 1 INTERCEPT-AD trial support pharmacology of ACU193 and role of amyloid beta oligomers in Alzheimer’s diseaseCash, cash equivalents and marketable securities of $282.7 million as of Sept. 30, 2023, expected to...

Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date Planned acquisition by Kyowa Kirin valued at up to $477.6 million with an anticipated closing in the first quarter of 2024 Biologics License Application for OTL-200 in MLD accepted by U.S. FDA under Priority Review; PDUFA date set for March 18, 2024 Ten prospective newborn screening studies are active globally with approximately 200,000 babies screened Eight presentations at ESGCT highlighted the differentiated profile and potential broad applicability of the company’s HSC gene therapy platform BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced several business accomplishments along with its financial results for the quarter ended September 30, 2023. “With strong...

— Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 — SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2023 and provided business updates. “We continue to be encouraged by the totality of evidence supporting clinical development of EFX for both pre-cirrhotic and cirrhotic NASH,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “We look forward to enrolling the first patients in our Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies later this year.” Phase...

HOUSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) — Drilling Tools International Corp., (“DTI” or the “Company”) (Nasdaq: DTI), a leading oilfield services company that manufactures and provides a differentiated, rental-focused offering of tools for use in horizontal and directional drilling, operating from 20 locations across North America, Europe and the Middle East, today reported its financial and operational results for the third quarter ended September 30, 2023. Third Quarter Financial HighlightsNet Revenue of $38.1 million increased 4.4% from $36.5 million in Q3 2022 Operating expenses of $(31.0) million were higher compared to $(28.5) million in Q3 2022 Net Income was $4.3 million, compared to $7.0 million in Q3 2022 Diluted Earnings Per Share were $0.14, compared to $0.36 in Q3 2022 Adjusted EBITDA was $12.7 million, compared...

Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitis IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, based on initial results from Phase 1 single-ascending dose and 300 mg multiple-ascending dose studies IMVT-1402 showed no statistically significant dose-related decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohort VTAMA® (tapinarof) cream, 1% net product revenue was $18.4M for the quarter ended September 30, 2023, with over 250,000 prescriptions written by approximately...

Third Quarter 2023 Revenues were $37.9 Million Representing an 18% Increase Year-over-Year; Nine Month 2023 Revenues of $106.1 Million, Up 26% Year-over-Year Third Quarter 2023 Adjusted EBITDA of $7.9 Million Representing a 31% Increase Year-over-Year; Nine Month 2023 Adjusted EBITDA of $17.7 Million, Up 67% Year-over-Year Strong Third Quarter Results and Positive Outlook for Fourth Quarter Support Reiteration of Fiscal Year 2023 Revenue and Adjusted EBITDA Guidance Multiple Recent Achievements with CYTOGAM®, including Availability of Product Manufactured by the Company for U.S. Commercial Sale and Presentation of New Clinical Data Received Shareholder Approval and Subsequently Closed $60 Million Private Placement with FIMI Opportunity Funds Conference Call and Live Webcast Today at 8:30 AM ETREHOVOT, Israel and HOBOKEN, N.J., Nov....

ATHENS, Greece, Nov. 13, 2023 (GLOBE NEWSWIRE) — Capital Product Partners L.P. (the “Partnership”, “CPLP” or “we” / “us”) (NASDAQ: CPLP), an international owner of ocean-going vessels, today released its financial results for the third quarter ended September 30, 2023. Highlights  Three-month periods ended September 30,  2023 2022 Increase / (decrease)Revenues $95.5 million $71.9 million 33%Expenses $51.0 million $40.4 million 26%Net Income $17.0 million $58.7 million (71%)Net Income per common unit $0.84 $2.90 (71%)Less: Gain on sale of vessels – $47.3 million –Adjusted Net Income (excluding gain on sale of vessels)1 $17.0 million $11.5 million 48%Adjusted Net Income per common unit (excluding gain on sale of vessels)1 $0.84 $0.57 47%Average number of vessels2 23.0 19.4 19%Operating...

MESA, Ariz., Nov. 13, 2023 (GLOBE NEWSWIRE) — Nxu, Inc., (NASDAQ: NXU) (“Nxu”, “the Company”), a domestic technology company developing and manufacturing innovative EV charging and energy storage solutions for the infrastructure we need to power our electrified future, today announced financial results for the quarter ended September 30, 2023. Nxu’s complete third quarter 2023 financial results and management commentary can be found by accessing the Company’s shareholder letter on the Investor Relations page of the Company’s website. “We successfully launched our Nxu One Megawatt+ Charging System in the third quarter, delivering the superior, powerful EV charging experience customers want and need. This was a pivotal quarter for us, transitioning from a development company to a revenue-generating company offering innovative products...

TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) — Marathon Gold Corporation (“Marathon” or the “Company”; TSX: MOZ) today announces its financial results for the third quarter ending September 30, 2023, and provides an update on the Company’s activities at the Valentine Gold Project (the “Project”) in the central region of Newfoundland and Labrador (“NL”). All figures are in Canadian dollars unless otherwise noted. Third Quarter Financial ResultsCash and cash equivalents at September 30, 2023 of $71.0 million and restricted cash of $244.8 million. Capital Expenditures of $76.0 million for the three months ended September 30, 2023, including $73.7 million related to construction of the Project.Third Quarter Project KPIsThe Project exceeded 800,000 hours of site work completed without a lost time incident. At the end of the third quarter,...